MiRNA-107 enhances the malignant progression of pancreatic cancer by targeting TGFBR3

Tian, Tingke; Yang, Qingmei; Zhang, Cuijuan; Li, Xiaokun; Cheng, Jiancheng

doi:10.1371/journal.pone.0249375

Cited by 12 publications

(6 citation statements)

References 31 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A significant correlation was observed between high expression levels of miRNAs-210, -155, -203 and -222 and reduced survival of patients with pancreatic tumors by up to 6.2 times [9]. The miR-107 in pancreatic cancer is associated with increased incidence and poor prognosis and may be involved in the possibility of metastasis and invasion through the TGFBR3 regulatory pathway [39].…”

Section: Discussionmentioning

confidence: 93%

Untitled

2021

Oncotarget

View full text Add to dashboard Cite

Diagnosis and treatment of pancreatic ductal adenocarcinoma (PA) remains a challenge in clinical practice. The aim of this study was to assess the role of microRNAs (miRNAs-21, -23a, -100, -107, -181c, -210) in plasma and tissue as possible biomarkers in the diagnosis of PA. Samples of plasma (PAp-n = 13), pancreatic tumors (PAt-n = 18), peritumoral regions (PPT-n = 9) were collected from patients during the surgical procedure. The control group consisted of samples from patients submitted to pancreatic surgery for trauma or cadaveric organs (PCn = 7) and healthy volunteers donated blood (PCp-n = 6). The expression profile of microRNAs was measured in all groups using RT-PCR, serum CA19-9 levels were determined in PA and PC. In tissue samples, there was a difference in the expression of miRNAs-21, -210 (p < 0.05) across the PAt, PC and PPT groups. The PAp showed overexpression of miRNAs-181c, -210 (p < 0.05) when compared to PCp. The combination of miRNAs-21, -210 tissue expression and serum CA19-9 showed 100% accuracy in the diagnosis of PA, as well as miR-181c expression in the plasma (PApxPCp). The expression of microRNAs in plasma proved to be a promising tool for a noninvasive detection test for PA, as well as further studies will evaluate the utility of microRNAs expression as biomarkers for prognostic and response to therapy in PA.

show abstract

Section: Discussionmentioning

confidence: 93%

Untitled

2021

Oncotarget

View full text Add to dashboard Cite

show abstract

“…It has been shown that miRNA was involved in the progression of PC. Tian et al found that miRNA-107 regulated TGFBR3 to promote the proliferation and metastasis of PC [ 37 ]. It was reported that miRNA-320b could inhibit PC proliferation through FOXM1 [ 38 ].To reveal the potential regulatory mechanisms of ECT2 and COL17A1 in PC, the ceRNA network was constructed.…”

Section: Discussionmentioning

confidence: 99%

Integrated Analysis of ECT2 and COL17A1 as Potential Biomarkers for Pancreatic Cancer

Huang

et al. 2022

Disease Markers

View full text Add to dashboard Cite

Background. Pancreatic cancer (PC) is a malignant tumor of the digestive tract. It presents with atypical clinical symptoms and lacks specific diagnostic indicators. This study is aimed at exploring the potential biomarkers of PC. Methods. TCGA database pancreatic cancer dataset was normalized and used to identify differentially expressed genes (DEGs). Survival, independent prognostic, and clinical correlation analyses were performed on DEGs to screen for key genes. DNA methylation, mutation, and copy number variation (CNV) analyses were used to analyze genetic variants in key genes. GSEA was performed to explore the functional enrichment of the key genes. Based on the expression of key genes, construction of a competing endogenous RNA (ceRNA) network, analysis of the tumor microenvironment (TME), and prediction of chemotherapeutic drug sensitivity were performed. Furthermore, the GEO database was used to validate the reliability of key genes. Results. Two key genes (ECT2 and COL17A1) were identified, which were highly expressed in PC. The mRNA expression of ECT2 and COL17A1 was associated with DNA methylation and CNV. The cell cycle, proteasome, and pathways in cancer were enriched in the high-COL17A1 and ECT2 groups. The TME results showed that immune scores were decreased in the high-ECT2 group. CeRNA network results showed that there were eleven miRNAs were involved in the regulation of ECT2 and COL17A1. Moreover, pRRophetic analysis showed that 20 chemotherapeutic drugs were associated with ECT2 and COL17A1 expression. Conclusions. Collectively, ECT2 and COL17A1 may be potential biomarkers for PC, providing a new direction for clinical diagnosis and treatment.

show abstract

“…Only 4 miRNAs, including miR-103a-3p, miR-107, miR-130b-3p and miR-96–5p, were negatively linked with XIST in more than 3 types of cancers. All of these 4 miRNAs played promoting roles in carcinogenesis by targeting mRNAs [ 45 , 46 , 47 , 48 ]. Therefore, XIST might function as a tumor suppressor LncRNA by sponging these onco-miRNAs.…”

Section: Discussionmentioning

confidence: 99%